

# **°Guide to Drug Development: a Comprehensive Review & Assessment**

Bert Spilker

**ISBN 9780781774246**

## **Contents**

About the Author xi

Preface xiii

Acknowledgments xv

Abbreviations xvii

### **SECTION 1 - Introduction and Overview of a Company and the Industry**

1 Introduction to Drug Development --- 3

2 Pharmaceutical Industry: Definitions --- 8

3 The Big Picture --- 15

4 Standards: Types, Uses, and Issues --- 34

5 Pharma-think, Academic-think, and

Government-think --- 45

6 Pharma Sense versus Common Sense --- 55

### **SECTION 2 - Basic Principles, Strategies, and Approaches**

7 Overview of Factors Affecting Drug Discovery --- 61

8 The Drug Discovery Process --- 68

9 Golden Rules of Drug Discovery --- 97

10 The Drug Development Process --- 104

11 Golden Rules of Drug Development --- 114

12 Biotechnology --- 119

13 Extrapolating Animal Safety and Efficacy Data to Humans --- 132

14 Evaluating and Interpreting Data --- 143

15 Stimulating Innovation and Increasing Efficiency with the Right Questions, People, Milieu, and Approaches --- 151

16 A New Paradigm of Drug Development --- 167

17 Future Environments for Drug Discovery and Development --- 172

### **SECTION 3 - Corporate Organization and Management Issues**

18 Models of International Operations --- 183

19 Organization at the Corporate Level --- 191

20 Corporate Management --- 202

21 Reducing Pharmaceutical Risk --- 225

22 Enhancing Communication --- 231

- 23 Personnel and Staffing Issues --- 246
- 24 Competitive Intelligence --- 261
- 25 Conflicts of Interest and Bias --- 266
- 26 Crisis Management --- 280
- 27 Mergers, Joint Ventures, and Alliances --- 287
- 28 Pharmacopolitics --- 298
- 29 Institutional Memory --- 308
- 30 Differences among Pharmaceutical Companies --- 315

#### SECTION 4 - External Corporate Relationships and Interactions

- 31 Interactions and Relationships between Academicians and Industry --- 331
- 32 Investigator-sponsored Research Proposals Submitted to Industry --- 341
- 33 Technology Transfer from Academia to Industry --- 345
- 34 Interactions between Pharmaceutical Companies --- 349
- 35 Interactions with Trade Associations --- 354
- 36 Interactions with Legislators and Government Agencies --- 359
- 37 Interactions and Relationships with Healthcare Professionals --- 370
- 38 Interactions with Patients and the Public --- 374
- 39 Patient Package Inserts --- 384
- 40 Interactions and Relationships with the Media --- 391

#### SECTION 5 - Research and Development Organization, Management, and Assessments

- 41 Organizing Research and Development --- 401
- 42 Managing Research and Development and Avoiding Tangents --- 410
- 43 Personnel Issues in Drug Discovery and Development --- 429
- 44 Myths about the Pharmaceutical Industry and Drug Development --- 436
- 45 Fads and Fashions in Drug Development --- 441
- 46 The Many Facets of Reality: Approaches to Issues and Problems --- 446
- 47 International Organization and Management --- 451
- 48 Project Management: Balancing Line Function and Matrix Approaches --- 460
- 49 Choosing the Number and Types of Drugs to Develop --- 475
- 50 Choosing Standards for Developing Drugs --- 480
- 51 Creating and Using Benchmarks --- 489
- 52 Evaluating a Portfolio of Investigational Drug Projects 496
- 53 Compassionate Use Programs --- 529

- 54 Virtual Drug Development --- 533
- 55 Developing and Marketing Orphan Drugs for Rare Diseases --- 544
- 56 Productivity and Project Success --- 553
- 57 Overview of Safety and Risk Management --- 569
- 58 Developing Standard Operating Procedures --- 578

## SECTION 6 - Clinical Activities and Issues

- 59 Introduction to Clinical Trials --- 589
- 60 Creating a Clinical Strategy and Development Plan for a New Drug or Indication --- 603
- 61 Designing and Implementing a Clinical Trial --- 615
- 62 Questions to Ask about a Clinical Trial Protocol --- 640
- 63 Dose-response Relationships in Clinical Trials --- 644
- 64 Collecting and Interpreting Life Events Data in Clinical Trials --- 655
- 65 Quality of Life and Pharmacoeconomics in Clinical Trials --- 662
- 66 Overview of Phase 4 and Postapproval Clinical Activities --- 677
- 67 Phase 4 Trials and Postapproval Pharmacovigilance Methodologies --- 685
- 68 Feasibility of Multinational Trials --- 693
- 69 Groups that Influence Protocol Design --- 707
- 70 Monitoring and Auditing a Clinical Trial --- 712
- 71 Electronic Data Collection and E-clinical Trials --- 721
- 72 Principles of Patient Recruitment and Retention --- 733
- 73 Surrogate Endpoints and Biomarkers --- 737
- 74 Contract Research Organizations and Outsourcing Strategies --- 746
- 75 Conducting Clinical Trials Efficiently and Rapidly --- 756
- 76 Clinical Significance --- 765
- 77 Incorporating Benefit-to-risk Determinations in Drug Development --- 771
- 78 Interactions between Clinicians and Statisticians for Analysis and Interpretation of Clinical Data --- 780
- 79 The Concept of Normalcy --- 787
- 80 Recruiting and Training Clinical Investigators --- 797
- 81 Human Subject Protection and Ethical Issues in Clinical Trials --- 807
- 82 Improving the Standards of Clinical Trial Publications .819
- 83 Registries and Directories of Clinical Trials, plus Disclosure of Their Results and Archiving Their Data --- 823
- 84 Clinical Trials Come of Age --- 832

## SECTION 7 - Regulatory Affairs Activities and Issues

- 85 Introduction to Regulatory Affairs --- 841
- 86 Negotiating and Interacting with Regulatory Agencies --- 859
- 87 Learning Which Regulatory Guidances and Standards May Be Modified --- 867
- 88 Preparing for and Holding Meetings with Regulatory Agencies --- 873
- 89 Food and Drug Administration Advisory Committee Meetings --- 884
- 90 Regulatory Applications for Marketing Approval and Global Interactions with Regulators --- 891
- 91 Regulatory Strategies in Real-life Product Development --- 902

## SECTION 8 - Marketing Activities, Issues, and Interactions with Medical Affairs

- 92 Overview of Marketing Activities and Issues --- 911
- 93 Corporate Issues Regarding the Medical Marketing Interface --- 946
- 94 Organizational and Staffing Issues Regarding the Medical Marketing Interface --- 954
- 95 Marketing Needs, Wants, and Issues in Developing Drugs --- 963
- 96 Joint Medical and Marketing Activities --- 972
- 97 Switching Prescription Drugs to Over-the-counter Status --- 986
- 98 Costs and Pricing --- 993
- 99 Providing Product Information to Healthcare Professionals --- 1007

## SECTION 9 - Functional Activities and Issues

- 100 Information Management --- 1021
- 101 Selected Statistical Issues --- 1038
- 102 Data Management --- 1049
- 103 Toxicology Activities and Issues --- 1058
- 104 Animal Testing and Animal Welfare --- 1065
- 105 Pharmacokinetics --- 1072
- 106 Licensing Activities and Issues --- 1077
- 107 Technical Development Activities and Issues --- 1102
- 108 Production Activities and Issues --- 1119
- 109 Patent Activities and Issues --- 1144
- 110 Legal Activities and Issues --- 1159
- 111 Financial Activities and Issues --- 1172

SECTION 10 - Overview of Current and Future Development

112 Poor Development and Corporate Practices: Threats to a Pharmaceutical Organization --- 1191

113 Keys for Pharmaceutical and Development Success --- 1201

114 Computer Simulations and Modeling --- 1214

115 The Future of Drug Discovery and Development --- 1221

SECTION 11 - Case Studies in Clinical Development, Regulatory Affairs, and the Management of Drug Development

116 Clinical Case Studies --- 1231

117 Regulatory Affairs Case Studies --- 1237

118 Management of Drug Development Case Studies -- 1244

Index 1251